Current medical trials aimed to neutralize IL-17 or IL-23 have shown to be highly effective in humans in the treatment of psoriasis and show promising initial results in ankylosing spondylitis and multiple sclerosis [65]. This evidence concerns the gene IL17A and multiple sclerosis.